ZA200301182B - Process for making N-aryl-anthranilic acids and their derivatives. - Google Patents
Process for making N-aryl-anthranilic acids and their derivatives. Download PDFInfo
- Publication number
- ZA200301182B ZA200301182B ZA200301182A ZA200301182A ZA200301182B ZA 200301182 B ZA200301182 B ZA 200301182B ZA 200301182 A ZA200301182 A ZA 200301182A ZA 200301182 A ZA200301182 A ZA 200301182A ZA 200301182 B ZA200301182 B ZA 200301182B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- alkyl
- hydrogen
- process according
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 174
- 230000008569 process Effects 0.000 title claims description 174
- 239000002253 acid Substances 0.000 title claims description 14
- 150000007513 acids Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 133
- 229910052739 hydrogen Inorganic materials 0.000 claims description 120
- 125000000217 alkyl group Chemical group 0.000 claims description 117
- 239000001257 hydrogen Substances 0.000 claims description 115
- 125000004432 carbon atom Chemical group C* 0.000 claims description 86
- 125000000623 heterocyclic group Chemical group 0.000 claims description 76
- 125000003118 aryl group Chemical group 0.000 claims description 68
- 150000003839 salts Chemical class 0.000 claims description 64
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 58
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 55
- 229910052751 metal Inorganic materials 0.000 claims description 50
- 239000002184 metal Substances 0.000 claims description 50
- 229910052757 nitrogen Inorganic materials 0.000 claims description 50
- 150000001768 cations Chemical class 0.000 claims description 49
- 125000003342 alkenyl group Chemical group 0.000 claims description 48
- -1 cation hydride Chemical class 0.000 claims description 46
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 36
- 125000005842 heteroatom Chemical group 0.000 claims description 32
- 125000005843 halogen group Chemical group 0.000 claims description 31
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 31
- 229910052760 oxygen Inorganic materials 0.000 claims description 29
- 229910052717 sulfur Inorganic materials 0.000 claims description 29
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- 125000001246 bromo group Chemical group Br* 0.000 claims description 27
- 125000002346 iodo group Chemical group I* 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 25
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 125000000304 alkynyl group Chemical group 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 22
- 125000001153 fluoro group Chemical group F* 0.000 claims description 18
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 17
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 14
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical group FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 230000002194 synthesizing effect Effects 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 claims description 9
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 claims description 9
- 229910000103 lithium hydride Inorganic materials 0.000 claims description 9
- 125000006413 ring segment Chemical group 0.000 claims description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 229960005235 piperonyl butoxide Drugs 0.000 claims description 7
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 7
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 6
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 6
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 6
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 6
- 239000012312 sodium hydride Substances 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 claims description 3
- LEEANUDEDHYDTG-UHFFFAOYSA-N 1,2-dimethoxypropane Chemical compound COCC(C)OC LEEANUDEDHYDTG-UHFFFAOYSA-N 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 claims description 3
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 claims description 3
- RVDLHGSZWAELAU-UHFFFAOYSA-N 5-tert-butylthiophene-2-carbonyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)S1 RVDLHGSZWAELAU-UHFFFAOYSA-N 0.000 claims description 3
- ZOUTYVWHWSUKPL-NOZJJQNGSA-N C[C@H](CS)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O Chemical group C[C@H](CS)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(O)=O ZOUTYVWHWSUKPL-NOZJJQNGSA-N 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 229960004132 diethyl ether Drugs 0.000 claims description 3
- 150000004678 hydrides Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 53
- KCNKJCHARANTIP-SNAWJCMRSA-N allyl-{4-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-but-2-enyl}-methyl-amine Chemical compound C=1OC2=CC(OC/C=C/CN(CC=C)C)=CC=C2C=1C1=CC=C(Br)C=C1 KCNKJCHARANTIP-SNAWJCMRSA-N 0.000 claims 13
- SYGWYBOJXOGMRU-UHFFFAOYSA-N chembl233051 Chemical compound C1=CC=C2C3=CC(C(N(CCN(C)C)C4=O)=O)=C5C4=CC=CC5=C3SC2=C1 SYGWYBOJXOGMRU-UHFFFAOYSA-N 0.000 claims 13
- 150000001408 amides Chemical class 0.000 claims 6
- 150000001735 carboxylic acids Chemical class 0.000 claims 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 claims 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 claims 4
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims 2
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 2
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 229940006487 lithium cation Drugs 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 claims 1
- 102100038494 Nuclear receptor subfamily 1 group I member 2 Human genes 0.000 claims 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims 1
- 229910006069 SO3H Inorganic materials 0.000 claims 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims 1
- 239000003377 acid catalyst Substances 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- YHNRUSMOYCDMJS-UHFFFAOYSA-N o-(cyclopropylmethyl)hydroxylamine Chemical compound NOCC1CC1 YHNRUSMOYCDMJS-UHFFFAOYSA-N 0.000 claims 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 description 17
- 108091054455 MAP kinase family Proteins 0.000 description 17
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 13
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 13
- 102000016914 ras Proteins Human genes 0.000 description 11
- 108091000080 Phosphotransferase Proteins 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 4
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 108030004793 Dual-specificity kinases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001702 Intracellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010068964 Intracellular Signaling Peptides and Proteins Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
- C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
- C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22820600P | 2000-08-25 | 2000-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200301182B true ZA200301182B (en) | 2004-05-12 |
Family
ID=22856235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200301182A ZA200301182B (en) | 2000-08-25 | 2003-02-12 | Process for making N-aryl-anthranilic acids and their derivatives. |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1313694A1 (zh) |
JP (1) | JP2004507518A (zh) |
KR (1) | KR20030059115A (zh) |
CN (1) | CN1458921A (zh) |
AP (1) | AP2001002249A0 (zh) |
AR (1) | AR032175A1 (zh) |
AU (1) | AU2001277044A1 (zh) |
BG (1) | BG107635A (zh) |
BR (1) | BR0113520A (zh) |
CA (1) | CA2420003A1 (zh) |
CZ (1) | CZ2003477A3 (zh) |
DO (1) | DOP2001000238A (zh) |
EA (1) | EA200300187A1 (zh) |
GT (1) | GT200100174A (zh) |
HN (1) | HN2001000216A (zh) |
HU (1) | HUP0300828A2 (zh) |
IL (1) | IL154507A0 (zh) |
IS (1) | IS6724A (zh) |
MA (1) | MA26949A1 (zh) |
MX (1) | MXPA03001654A (zh) |
NO (1) | NO20030844L (zh) |
PA (1) | PA8526501A1 (zh) |
PE (1) | PE20020393A1 (zh) |
PL (1) | PL360699A1 (zh) |
SK (1) | SK2072003A3 (zh) |
SV (1) | SV2002000601A (zh) |
TN (1) | TNSN01127A1 (zh) |
UY (1) | UY26908A1 (zh) |
WO (1) | WO2002018319A1 (zh) |
YU (1) | YU14303A (zh) |
ZA (1) | ZA200301182B (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2275102E (pt) | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
NZ546011A (en) | 2003-10-21 | 2009-09-25 | Warner Lambert Co | Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
WO2005051301A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
RU2006121990A (ru) | 2003-11-21 | 2007-12-27 | Эррэй Биофарма Инк. (Us) | Ингибиторы протеинкиназ акт |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
PT2332909E (pt) | 2005-04-13 | 2014-12-17 | Astex Therapeutics Ltd | Derivados de hidroxibenzamida e sua utilização como inibidores de hsp90 |
AR055057A1 (es) | 2005-05-18 | 2007-08-01 | Array Biopharma Inc | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
DE602007011628D1 (de) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren |
CA2656364C (en) | 2006-07-06 | 2014-11-25 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
ATE523499T1 (de) | 2006-07-06 | 2011-09-15 | Array Biopharma Inc | Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer |
US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
EP2081891A2 (en) | 2006-10-12 | 2009-07-29 | Astex Therapeutics Limited | Pharmaceutical compounds having hsp90 inhibitory or modulating activity |
EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
US9730912B2 (en) | 2006-10-12 | 2017-08-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
TWI450720B (zh) | 2007-07-05 | 2014-09-01 | Array Biopharma Inc | 作為akt蛋白質激酶抑制劑之嘧啶環戊烷 |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US8377937B2 (en) | 2007-07-05 | 2013-02-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
ES2401685T3 (es) | 2008-01-09 | 2013-04-23 | Array Biopharma, Inc. | Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT |
AU2009204025B2 (en) | 2008-01-09 | 2014-02-20 | Array Biopharma Inc. | Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
CN101985428B (zh) * | 2009-07-29 | 2014-02-12 | 杭州民生药业有限公司 | 邻苯胺基苯甲酸衍生物或其药学上可接受的盐、其制备方法及其用途 |
CA2789361A1 (en) * | 2010-02-19 | 2011-08-25 | Jacques Mortier | Method for preparing chemical compounds of interest by aromatic nucleophilic substitution |
EP2536682A1 (fr) * | 2010-02-19 | 2012-12-26 | Centre National De La Recherche Scientifique | Procede de preparation de composes chimiques d'interet par substitution nucleophile aromatique de derives d'acides carboxyliques aromatiques portant au moins un groupement electroattracteur |
CN103841976A (zh) | 2011-04-01 | 2014-06-04 | 基因泰克公司 | Akt和mek抑制剂化合物的组合及其使用方法 |
CN103874689B (zh) | 2011-04-01 | 2016-04-27 | 基因泰克公司 | Akt抑制剂化合物和威罗菲尼的组合及使用方法 |
MY186549A (en) * | 2012-10-12 | 2021-07-26 | Exelixis Inc | Novel process for making compounds for use in the treatment of cancer |
CN112745237B (zh) * | 2019-10-29 | 2023-06-20 | 中国科学院上海药物研究所 | 2-芳基胺类化合物及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3138636A (en) * | 1960-06-23 | 1964-06-23 | Parke Davis & Co | Anthranilic acid derivatives |
WO1998037881A1 (en) * | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
WO1999001426A1 (en) * | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
DE69836378T2 (de) * | 1997-07-01 | 2007-10-11 | Warner-Lambert Co. Llc | Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren |
CA2348236A1 (en) * | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
CN1213997C (zh) * | 1999-04-21 | 2005-08-10 | 沃尼尔·朗伯公司 | 制备-2-(n-苯基氨基)苯甲酸衍生物的方法 |
-
2001
- 2001-07-20 CZ CZ2003477A patent/CZ2003477A3/cs unknown
- 2001-07-20 AU AU2001277044A patent/AU2001277044A1/en not_active Abandoned
- 2001-07-20 KR KR10-2003-7002675A patent/KR20030059115A/ko not_active Application Discontinuation
- 2001-07-20 AP APAP/P/2001/002249A patent/AP2001002249A0/en unknown
- 2001-07-20 EA EA200300187A patent/EA200300187A1/ru unknown
- 2001-07-20 YU YU14303A patent/YU14303A/sh unknown
- 2001-07-20 JP JP2002523437A patent/JP2004507518A/ja active Pending
- 2001-07-20 WO PCT/US2001/022948 patent/WO2002018319A1/en not_active Application Discontinuation
- 2001-07-20 CN CN01815869A patent/CN1458921A/zh active Pending
- 2001-07-20 IL IL15450701A patent/IL154507A0/xx unknown
- 2001-07-20 BR BR0113520-1A patent/BR0113520A/pt not_active Application Discontinuation
- 2001-07-20 MX MXPA03001654A patent/MXPA03001654A/es unknown
- 2001-07-20 EP EP01954824A patent/EP1313694A1/en not_active Withdrawn
- 2001-07-20 PL PL36069901A patent/PL360699A1/xx unknown
- 2001-07-20 SK SK207-2003A patent/SK2072003A3/sk unknown
- 2001-07-20 HU HU0300828A patent/HUP0300828A2/hu unknown
- 2001-07-20 CA CA002420003A patent/CA2420003A1/en not_active Abandoned
- 2001-08-15 SV SV2001000601A patent/SV2002000601A/es not_active Application Discontinuation
- 2001-08-22 TN TNTNSN01127A patent/TNSN01127A1/en unknown
- 2001-08-23 PA PA20018526501A patent/PA8526501A1/es unknown
- 2001-08-24 GT GT200100174A patent/GT200100174A/es unknown
- 2001-08-24 UY UY26908A patent/UY26908A1/es not_active Application Discontinuation
- 2001-08-24 PE PE2001000853A patent/PE20020393A1/es not_active Application Discontinuation
- 2001-08-24 AR ARP010104047A patent/AR032175A1/es unknown
- 2001-08-24 DO DO2001000238A patent/DOP2001000238A/es unknown
- 2001-09-26 HN HN2001000216A patent/HN2001000216A/es unknown
-
2003
- 2003-02-12 ZA ZA200301182A patent/ZA200301182B/en unknown
- 2003-02-20 IS IS6724A patent/IS6724A/is unknown
- 2003-02-24 NO NO20030844A patent/NO20030844L/no not_active Application Discontinuation
- 2003-03-13 BG BG107635A patent/BG107635A/bg unknown
- 2003-03-14 MA MA27069A patent/MA26949A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
SV2002000601A (es) | 2002-04-03 |
MA26949A1 (fr) | 2004-12-20 |
AR032175A1 (es) | 2003-10-29 |
PE20020393A1 (es) | 2002-05-09 |
EP1313694A1 (en) | 2003-05-28 |
GT200100174A (es) | 2002-07-18 |
DOP2001000238A (es) | 2003-01-31 |
AU2001277044A1 (en) | 2002-03-13 |
NO20030844D0 (no) | 2003-02-24 |
BR0113520A (pt) | 2003-06-24 |
PA8526501A1 (es) | 2002-07-30 |
YU14303A (sh) | 2006-08-17 |
CZ2003477A3 (cs) | 2003-10-15 |
PL360699A1 (en) | 2004-09-20 |
IS6724A (is) | 2003-02-20 |
HN2001000216A (es) | 2002-05-22 |
UY26908A1 (es) | 2001-11-30 |
KR20030059115A (ko) | 2003-07-07 |
HUP0300828A2 (hu) | 2003-09-29 |
NO20030844L (no) | 2003-02-25 |
TNSN01127A1 (en) | 2005-11-10 |
CA2420003A1 (en) | 2002-03-07 |
SK2072003A3 (en) | 2004-01-08 |
JP2004507518A (ja) | 2004-03-11 |
CN1458921A (zh) | 2003-11-26 |
EA200300187A1 (ru) | 2003-08-28 |
IL154507A0 (en) | 2003-09-17 |
WO2002018319A1 (en) | 2002-03-07 |
MXPA03001654A (es) | 2004-09-10 |
BG107635A (bg) | 2004-09-30 |
AP2001002249A0 (en) | 2001-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200301182B (en) | Process for making N-aryl-anthranilic acids and their derivatives. | |
JP4631703B2 (ja) | ピリミジン−4−オン化合物の製造方法 | |
Hanefeld et al. | One-pot synthesis of tetrasubstituted pyrazoles—proof of regiochemistry | |
NO180750B (no) | Pyrazolopyrimidinoner som antianginale midler | |
CA3096963A1 (en) | A new method for synthesis of deuterated amide and deuterated sulfonamide | |
TW200922582A (en) | N-benzyl, N'-arylcarbonylpiperazine derivatives | |
Mukaiyama et al. | Synthesis and c-Src inhibitory activity of imidazo [1, 5-a] pyrazine derivatives as an agent for treatment of acute ischemic stroke | |
Hamblett et al. | The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors | |
Fiore et al. | N-triflyl-propiolamides: Preparation and transamidation reactions | |
CA2687750A1 (en) | Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture | |
TWI233924B (en) | Process for trans-4-amino-1-cyclohexane carboxylic acid derivatives | |
Chakraborty et al. | Cyclic trimer of 5-(aminomethyl)-2-furancarboxylic acid as a novel synthetic receptor for carboxylate recognition | |
Rozentsveig et al. | Amidine derivatives of α-arylglycines from N-(1-aryl-2, 2, 2-trichloroethyl) amides of arenesulfonic acids and secondary amines | |
JPWO2006035937A1 (ja) | (1,3−ジ置換インドリル)尿素誘導体の製造方法及びその製造中間体並びにその製造方法 | |
AU758207B2 (en) | Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same | |
KR20150056541A (ko) | 시타글립틴 및 중간체 화합물의 제조 방법 | |
Heras et al. | Reaction of α-iminomethylene amino esters with mono-and bidentate nucleophiles: a straightforward route to 2-amino-1H-5-imidazolones | |
Cho et al. | Synthesis of pyrroloazepines. Facile synthesis of 2‐substituted pyrrole derivatives by the phosgene method | |
Merzhyievskyi et al. | Functionalized 5‐Amino‐4‐cyanoxazoles, their Hetero‐and Macrocyclic Derivatives: Preparation and Synthetic Applications | |
US6313294B1 (en) | Process for preparing amides | |
Casabona et al. | Efficient synthesis of a new pipecolic acid analogue with a bicyclic structure | |
Yamamoto et al. | Synthesis of substituted benzimidazoles via tosylation of N-aryl amidoxime | |
JP5130211B2 (ja) | 3−ヒドラジノ−2,5−ジオキソピロリジン−3−カルボキシレート類およびその製造方法ならびにその使用 | |
Glushkov et al. | Synthesis and antiinflammatory and analgesic activity of amidines of 3, 4-dihydroisoquinoline series | |
US20020058815A1 (en) | Methods for synthesis of amino-tertahydroisoquinoline-sulfonamide hydroxamic acids |